Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $13.78.

Several brokerages have recently weighed in on TEVA. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target on the stock in a research note on Friday, March 8th. Finally, Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $10.00 to $14.00 in a report on Tuesday, January 23rd.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the transaction, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at $132,062.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 390,738 shares of company stock worth $5,132,766. 0.62% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its holdings in shares of Teva Pharmaceutical Industries by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company’s stock worth $17,609,000 after purchasing an additional 28,920 shares during the period. PNC Financial Services Group Inc. boosted its stake in Teva Pharmaceutical Industries by 12.3% during the first quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company’s stock worth $1,118,000 after buying an additional 13,069 shares during the period. MetLife Investment Management LLC increased its position in shares of Teva Pharmaceutical Industries by 4.7% during the first quarter. MetLife Investment Management LLC now owns 95,953 shares of the company’s stock valued at $901,000 after acquiring an additional 4,300 shares during the last quarter. BlackRock Inc. increased its position in shares of Teva Pharmaceutical Industries by 3.7% during the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock valued at $391,081,000 after acquiring an additional 1,494,814 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in shares of Teva Pharmaceutical Industries by 4.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company’s stock valued at $4,137,000 after acquiring an additional 16,134 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 4.1 %

TEVA opened at $13.30 on Friday. The company has a fifty day moving average of $13.39 and a two-hundred day moving average of $11.13. The stock has a market capitalization of $14.91 billion, a price-to-earnings ratio of -28.30, a PEG ratio of 1.60 and a beta of 1.05. Teva Pharmaceutical Industries has a fifty-two week low of $7.09 and a fifty-two week high of $14.47. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.25. The firm had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. On average, research analysts expect that Teva Pharmaceutical Industries will post 2.28 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.